Abstract: Osteoporosis and osteoporotic fractures have a high impact on the quality of life of patients and on the financial aspects of Western health care systems. There is a tremendous need for improvement of the treatment outcome in osteoporotic fracture patients and biomaterials are of interest to stimulate fracture healing in those patients. For adequate characterization of biomaterials for the indication of osteoporotic fractures a clinically relevant animal model with a fracture defect in the metaphyseal region of a long bone in an osteoporotic animal is required. We recently developed a 3-5 mm wedge shaped osteotomy model in the distal metaphysis of the femur in osteoporotic rats. There are different biomaterials approaches to stimulate fracture healing in osteoporotic fractures and recently published results suggest that the composite implants from osteoconductive carriers combined with osteoanabolic agents, e.g., strontium-modified calcium phosphate cement, can enhance new bone formation. Further in vivo and clinical research will be necessary in the future for introduction of new and different types of biomaterials for osteoporotic fracture patients into all day clinical practice.
Introduction
Osteoporosis is a disease with a high impact on the quality of life of patients and on financial costs in Western health care systems. In osteoporotic bone the trabecular density decreases due to an imbalance of bone remodeling in favor of osteocatabolic processes. The activity of osteoclasts is increased in contrast to a less osteoblast activity. This leads to a decreased load-bearing capacity and subsequently to a higher fracture risk, especially in the cancellous areas, like the epiphysis and metaphysis, of the distal radius, proximal humerus, proximal femur or the vertebral bodies and to a lesser extent the diaphyseal part of long bones [1] [2] [3] [4] [5] [6] . The epiphysis and particular the metaphyseal area of long bones ensures the load transfer from the joint to the robust cortical part of the bone, the diaphysis. This is why these parts of the long bones are mainly vulnerable in osteoporotic bone [1, 2, 5] . Common osteoporotic fractures are on the hip and spine, which are associated in increasing mortality rate of 10%-20% [7] . Because of the initially reduced bone density due to osteoporosis, fractures often result in a broad defect zone and not only in a couple of fragments. Even low energy trauma, like falls in the flat, resulting in complex fractures with bony defects mainly located in the metaphyseal area of the long bones or impression fractures of the spine. Many efforts have been undertaken to support fracture healing and replace destroyed bone with biomaterials. Until now autogenous cancellous bone grafting is the gold standard to stimulate bone healing in fracture defects, despite of the resulting comorbidities at the donor site and the impaired osteogenic potential in elderly bone grafts [8] and especially in an osteoporotic bone status [9] .
Animal models
Preclinical testing of biomaterials requires clinical relevant animal models that allow simulation of the clinical relevant situation [10, 11] . Despite their relevance to osteoporotic fracture research and their overall importance in bone healing, mostly fractures in the diaphyseal area of the femur [4, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] or tibia [13] with intramedullary pin fixation [16, [25] [26] [27] [28] ] based on the model of Bonnarens and Einhorn [29] were studied. Furthermore, studies showed differences in bone healing involving less callus formation in the metaphyseal area with more endosteally bone healing than in the diaphysis during fracture healing [2, 3, 4, 30] . Regarding the pathophysiology of osteoporotic bone, several reports suggest deviations in healing patterns in osteoporotic bone from the normal course in diaphyseal fracture model and drill-hole defects [31] [32] [33] [34] [35] [36] [37] [38] [39] . Metaphyseal fracture healing was addressed only with a couple of models, which studied either a small sized gap [4, 18, 22, [40] [41] [42] a drill-hole defect [9, [43] [44] [45] [46] or partial osteotomy [1] . To investigate biomaterials in a fracture-defect situation, a gap of 0.5 mm as used in the study of Stürmer et al. [4] or 0.22 mm in the metaphyseal model of Histing et al. [40] is quite to small for the implantation of biomaterials. Furthermore, this gap will heal spontaneously without any need of stimulation after 5 weeks [40] even in osteoporotic bone [4] . Drill-hole defects or partial osteotomies do not fulfill the definition of a fracture with complete transection of all cortices. Another requirement to simulate the clinical situation of osteoporotic fracture-defects is the incidence of fractures in an existing osteopenic bone status. The mentioned study above generated the metaphyseal osteotomy simultaneously to the ovariectomy, thus an osteoporotic bone status was not yet established at the beginning of bone healing.
In the past, there was an enormous gap between available clinically relevant animal models to study bone healing in osteoporotic bone. A recently published consensus paper by Garcia et al. [10] about non-union and critical-size defects in rodent animal models as well as a comprehensive review of "In vivo models of bone repair" by Mills et al. [47] concluded that there is still an absence of metaphyseal fracture-defect models in osteoporotic bone. In our own work group, we recently published a new metaphyseal fracturedefect model [48] , which is focused on a critical-size defect to allow for characterization of biomaterials in osteoporotic bone induced by bilaterally ovariectomy and multi-deficiencies-diet [49, 50] . This fracture-defect model consists of a wedge-shaped osteotomy at the distal metaphysis of the femur. The basis of the triangular defect is 3 or 5 mm in length and placed at the lateral aspect of the femur, stabilized by a T-shaped mini-plate fixed at the lateral tensionband side of the bone ( Figure 1A and B). To reduce bending forces to the plate due to unilateral fixation, the tip of the defect, with a gap of 0.35 mm, is located at the medial part of the femur ( Figure 1C and D). All cortices were completely cut to guarantee a fracture situation. Histing et al. [26] showed in a comparative study in mice, that a mini-plate and an external fixator have the best rotational stiffness in comparison to all currently existing intramedullary fixation techniques for animal studies. To ensure the metaphyseal location of the fracture gap, a micro-CT analysis of the bone-outcut was performed and showed intact cancellous bone trabecula in transition to hollow bone confirming the right area. The size of the gap was generated precisely with a size of 3 ± 0.21 mm and 5 ± 0.24 mm, respectively. Quantitative µCT analysis demonstrated a completely healed 3 mm gap (Figure 2A -C) but a persistent gap without any cortical bridging of the fracture defect of 5 mm ( Figure 2D -F) after 42 days post-osteotomy [48] . Additionally, histological analysis showed signs of a non-healed critical-size defect with fibrous tissue inside the persistent defect zone without cortical bridging as well [48] . These findings are in line with findings from Mehta et al. [20] who generated an atrophic non-union in female rats even with normal bone status after 6 weeks in the diaphysis of the rats' femur. In summary, this new fracture-defect model allows for reliable investigation of biomaterials, in a clinical relevant animal model in osteoporotic bone (Figure 3 ).
Osteoporotic bone healing
Many studies suggest differences in bone healing in osteoporotic vs. physiological bone status [32, 35, 36, 37, 39] . In a comparative study between ovariectomized (OVX) and sham-operated (SHAM) rats, provided with a 3 mm wedgeshaped fracture-defect in the metaphyseal area of the femur, histological and biomechanical differences could be constituted. In the OVX group a significant reduced shear-rigidity in the former fractured metaphyseal area in comparison to the SHAM animals could be detected. Despite of a completely bridged fracture gap in both groups (OVX and SHAM), cartilage remnants, disarrangement of hypertrophic chondrocytes and the increased unmineralized tissue was seen in the fracture gap of the OVX rats indicating delayed healing in the OVX group. This is in line with a recent published work of Oliver et al. [37], where the fracture callus in the OVX group was filled with soft tissue and cartilage remnants. Fatty degradation of bone marrow in the elderly, which is associated with a decreased load-bearing capacity and accordingly a higher osteoporotic-related fracture risk, is regulated by beta-catenin-dependent Wnt signaling [8] . This pathway determines mesenchymal stem cells to differentiate into an osteogenic or adipogenic lineage, thus a manipulation of this signaling can influence the bone mass [8] . In osteoporotic bone, bone morphogenetic proteins (BMP) play also an important role by regulation of the BMPWnt-RANKL axis. BMPs up-regulate the expression of the Wnt-inhibitor DKK1 and sclerostin. β-catenin-related Wnt signaling induces the expression of osteoprotegerin (OPG) and suppresses RANKL. Therefor BMPs could lead to an increased activity of osteoclasts and consequently higher bone resorption [51] . On the other hand, i.e., BMP-2 and 4 promotes mesenchymal stem cells to differentiate to osteoblasts, increase their activity and lead to osteogenesis [51] . A necessity for bone healing, especially in a broad defect zone, is the angiogenic potential of a fracture site, because new blood vessel formations ensures the nutrient supply in this region [19, 52] . In an extensive study by Liu et al. [53] with application of dynamic contrast-enhanced VCT (DCE-VCT) and dynamic contrast-enhanced MRI (DCE-MRI) no differences in angiogenic response in osteoporotic bone could be detected in comparison to normal bone metabolism. But, also this study revealed a significant reduced bone density in the fracture defect of osteoporotic bone in contrast to the control group. In general, we are at the beginning to detect differences in fracture healing in osteoporotic versus physiological bone and further research, especially with an emphasis on affecting these interactions for the benefit of osteogenesis are necessary.
Biomaterials for osteoporotic fractures
Biomaterials with the potential to stimulate bone healing have gained interest to improve healing and outcome for patients with osteoporotic fractures [54] .
Injectable calcium phosphate cements have been used in bone surgery since many years based on their osteoconductive properties to stimulate new bone formation [55] . In addition, calcium phosphate cements (CPC) provide the feasibility as a drug-delivery system [56] . Thus, different agents could be added to CPC to improve new bone formation in a fracture-defect. Bisphosphonates like risedronate or zoledronate are established drugs for systemic treatment of osteoporosis. They have an impeding effect on osteoclasts and therefore can increase bone mass. An in vitro study with a calcium silicate cement (CSC) enriched with risedronate reports about a good release kinetic and no cytotoxic effect on osteoblasts [57] . CPC enhanced with zoledronate showed an increased bone density in µCT and histology and a higher bone mineral content in ovariectomized rats in comparison to the control group [58] . A major drawback of this study is the application of the CPC in the abdomen of the rats instead inside the bone. Thus, further studies have to prove the same osteoanabolic effect by application in a fracture-defect. As already mentioned above, BMP-2 has a stimulating effect on osteoblasts. Li et al. [59] report about a study with bone defects in osteoporotic goats vertebrae, filled with CPC charged with rhBMP-2 loaded gelatin microspheres. They show a greater bone mineralization rate in the rhBMP-2/ gelatin microsphere/CPC group than in all other control groups. In this study only a kind of drill-hole defect was chosen limiting the conclusion of this study on established fractures in patients. A comparable technique was performed by Hollinger et al. [34] . These authors enriched an injectable beta-tricalcium phosphate/collagen matrix with recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and detected a better biomechanical behavior 5 weeks after surgery than in the control group. Limitations of this model are the diaphyseal localization and the small width of only 0.2 mm of the defect. Additionally, the biomaterial was placed in the vicinity of the gap and not directly inside it. An interesting approach via gene technology is reported by Wang et al. [60] . They generated a calcium phosphate cement loaded with RANK siRNA inside PLGA-microparticles. In this in vitro study, an inhibition in osteoclastic formation due to a reduced bioactivity of RANK [60] was found. Further study on this sophisticated approach is warranted.
Strontium (II) (Sr
2+
) has been shown to effectively both stimulate bone formation and inhibit osteoclastic activity and has been introduced into all day clinical practice as oral strontium ranelate medication against osteoporosis [61, 62] . Local administration of strontium mainly from functionalized titanium implant surfaces [63] [64] [65] [66] [67] [68] or from strontium-substituted hydroxyapatite coatings [69, 70] gained interest to use the positive effects of strontium on new bone formation for better implant fixation. Schumacher et al. recently showed the possibility to generate a strontium (II) modified calcium α-tricalcium phosphate based phosphate cement (SrCPC) in which the CaCO 3 portion in the precursor mixture is replaced completely with strontium carbonate (SrCO 3 , 99.994%), resulting in Sr/Ca ratio of 0.123 [71] . The intention of this recently developed composite material is to use the osteoconductive calcium phosphate cement as a drug carrier for the local release of strontium into bone defects in order to leverage the osteoanabolic and anti-osteoclastic activity not in a systemic but local environment to achieve high strontium concentrations with subsequent enhancement of new bone formation. We recently reported that this strontium-enhanced SrCPC revealed a statistically significantly increased new bone formation with accelerated expression of BMP-2, osteocalcin, and OPG compared to plain CPC [72] . A high CD-31 expression showed concomitant new blood vessel formation. In order to elucidate the local release of Sr from SrCPC, TOF-SIMS analysis was used which showed a high release of strontium up to a distance of 5 mm to the implant. Sr, Ca and the collagen signal were found in the same areas of the newly formed bone suggesting that the released Sr from SrCPC was incorporated into the new bone [72] .
Allogeneic and autologous stem cell transplantation has also been considered for research in osteoporotic bone [9, 73] . Yu et al. [73] injected collagen I-coated PLGA microspheres enriched with allogeneic bone mesenchymal stem cells (BMSC's) from healthy rats into a drill-hole defect in the greater trochanter of osteoporotic rats. BMD, trabecular thickness, trabecular spacing and bone volume fraction were found to be better than in the control group. Cao et al. [9] reported about improved bone formation in a drill-hole defect in osteoporotic goats treated by autologous mesenchymal stem cells-enriched β-TCP. Another study group established a gene therapeutically technique for treatment of bone defects in osteoporotic bone. Zhang et al. [46] implanted a mesoporous bioglass/silk fibrin scaffold containing adenovirus-PDGFb and adenovirus-BMP-7 into a drill-hole defect in osteoporotic rats. After 4 weeks, significantly more new bone formation due to a recruitment of mesenchymal progenitor cells was found.
Conclusion
Osteoporosis and osteoporotic fractures have a high impact on the quality of life of patients and on the financial aspects of Western health care systems. There is a tremendous need for improvement of the treatment outcome in osteoporotic fracture patients and biomaterials are of interest to stimulate fracture healing in those patients. However, there is still a lack of adequately characterized biomaterials for this indication. Furthermore, there are only a very few adequate animal models for the characterization of biomaterials available. Recently published results suggest that the composite implants from osteoconductive carriers combined with osteoanablic agents, e.g., strontium-modified calcium phosphate cement, can enhance new bone formation. Further in vivo and clinical research will be necessary in the future for introduction of new and different types biomaterials for osteoporotic fracture patients into all day clinical practice.
